Business UpdateJun 2, 2026, 09:07 AM
Sensei Biotherapeutics Updates Business, PIKTOR Clinical Progress
AI Summary
Sensei Biotherapeutics filed an Amendment No. 1 to its Annual Report on Form 10-K, primarily to update its business section following SEC comments. The company completed the acquisition of Faeth Therapeutics on February 17, 2026, and secured $200 million in private placement financing. Its lead program, PIKTOR, a multi-node inhibitor for the PI3K/AKT/mTOR pathway, is advancing with topline data from a Phase 2 endometrial cancer trial expected by year-end 2026 and a Phase 1b breast cancer trial recently initiated. The company highlights PIKTOR's differentiated profile, including its oral formulation, potentially improved tolerability, and broad anti-tumor impact.
Key Highlights
- Sensei Biotherapeutics completed the acquisition of Faeth Therapeutics on February 17, 2026.
- The company received $200 million in gross proceeds from a private placement financing.
- PIKTOR, a multi-node inhibitor of the PI3K/AKT/mTOR pathway, is now the lead program.
- Topline data for the Phase 2 trial (FTH-PIK-201) in endometrial cancer is anticipated by year-end 2026.
- The first patient was dosed in the Phase 1b trial (FTH-PIK-101) for HR+/HER2- advanced breast cancer in May 2026.
- Prior Phase 1b study (X31025) showed 47% objective response rate and 73% clinical benefit rate in evaluable patients.
- January 2026 data snapshot from FTH-PIK-201 showed 13.6% any grade stomatitis and 4.5% grade 3/4 hyperglycemia.
Price Impact
More from SNSE